Show simple item record

dc.contributor.authorMurnane, D.
dc.contributor.authorMartin, G. P.
dc.contributor.authorMarriott, C.
dc.date.accessioned2015-03-19T09:03:43Z
dc.date.available2015-03-19T09:03:43Z
dc.date.issued2005-09
dc.identifier.citationMurnane , D , Martin , G P & Marriott , C 2005 , ' Investigation of a reverse-phase high performance liquid chromatography (RP-HPLC) method for a weakly basic drug ' , Journal of Pharmacy and Pharmacology , vol. 57 , no. Supp 1 , 180P , pp. S81 . https://doi.org/10.1211/002235705778248325
dc.identifier.issn0022-3573
dc.identifier.otherPURE: 398271
dc.identifier.otherPURE UUID: 1bfe3c5a-1a3b-42c6-a2da-730b2471252f
dc.identifier.otherWOS: 000203408200214
dc.identifier.urihttp://hdl.handle.net/2299/15646
dc.description.abstractFormulation development of combination drug products requires the availability of a rapid analytical method with low limits of detection, for the high-throughput analysis of the large number of samples generated. Salmeterol xinafoate (SX) and fluticasone propionate (FP) are coformulated for the treatment of asthma and COPD. RP-HPLC using C- 18 bonded phases of basic compounds, such as SX, can be problematic due to the occurrence of poor peak shapes. This can be overcome by decreasing the flow rate, modifying column temperature, careful selection of the column and use of methanol as organic modifier (McCalley 1999, 2000, 2002). The aim of this study was to examine the performance of SX on a second-generation silica bonded reverse-phase column, with a mobile phase containing a high content of organic modifier.en
dc.format.extent1
dc.language.isoeng
dc.relation.ispartofJournal of Pharmacy and Pharmacology
dc.titleInvestigation of a reverse-phase high performance liquid chromatography (RP-HPLC) method for a weakly basic drugen
dc.contributor.institutionHealth & Human Sciences Research Institute
dc.contributor.institutionSchool of Life and Medical Sciences
dc.contributor.institutionDepartment of Pharmacy
dc.contributor.institutionCentre for Research into Topical Drug Delivery and Toxicology
dc.contributor.institutionPharmaceutics
dc.contributor.institutionAirway Group
dc.contributor.institutionPharmaceutical Analysis and Product Characterisation
dc.description.statusPeer reviewed
dc.relation.school
dcterms.dateAccepted2005-09
rioxxterms.versionofrecordhttps://doi.org/10.1211/002235705778248325
rioxxterms.typeOther
herts.preservation.rarelyaccessedtrue


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record